source
- Arrowhead's RNAi drug Redemplo shows safety advantage over Ionis in late-stage triglyceride trialsAt the European Society of Cardiology meeting in Munich, Arrowhead Pharmaceuticals presented new data on its RNA interference candidate Redemplo. Redemplo was evaluated in two late-stage studies i…
- FDA grants approval to Revolution Medicines' Rasonque for pancreatic cancerThe U.S. Food and Drug Administration has approved Rasonque, a new therapy from Revolution Medicines, for the treatment of pancreatic cancer. The decision follows data that showed the drug nearly…